WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc.

September 18, 2007 16:27 ET

WEX Pharmaceuticals Inc.: Two Canadian Patents Issued

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 18, 2007) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to announce the official grant to the Company of Canadian Patent No. 2,485,337 under the title, "Analgesic Composition and Method" and Canadian Patent No. 2,493,885 under the title, "Use of Sodium Channel Blocking Compounds and Aspirin in Manufacturing Drugs for Producing Synergistically Analgesic Effect in Mammals".

Patent No. 2,485,337 claims a pharmaceutical analgesic composition comprising an opioid analgesic agent and a compound that binds to the SS1 or SS2 subunit of a sodium channel, such as tetrodotoxin and saxitoxin, and analogs thereof.

Patent No. 2,493,885 relates to the use of combinations of sodium channel blocking compounds and aspirin in manufacturing drugs for producing synergistic analgesic effects in mammals, in which said compounds bind to a subunit of SS1 or SS2 sites in the sodium channel.

Foreign counterparts of both patents have been previously issued in China and are pending in other countries.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.

Forward Looking Statements and Information

This News Release contains forward-looking statements which may not be based on historical fact. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information